Adenosine Or Derivative Patents (Class 514/46)
-
Publication number: 20120107276Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.Type: ApplicationFiled: December 28, 2011Publication date: May 3, 2012Applicant: Siga Technologies, Inc.Inventors: Dennis E. Hruby, Tove C. Bolken, Dongcheng Dai
-
Publication number: 20120094947Abstract: Methods for treating diseases in humans and vertebrate animals are provided using competitive antagonists of cellular metabolites combined with a protective agent for protecting host cells from toxic effects of the drugs. Also provided are kits comprising competitive antagonists and suitable protective agents. In addition, screening methods for identifying competitive antagonists, protective agents and potentiating agents, for use according to the methods of the invention, are provided.Type: ApplicationFiled: August 15, 2008Publication date: April 19, 2012Inventors: Adam Lubin, Martin Lubin
-
Patent number: 8158604Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here.Type: GrantFiled: February 24, 2010Date of Patent: April 17, 2012Assignee: University of Virginia Patent FoundationInventors: Joel M. Linden, Jayson M. Rieger, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
-
Publication number: 20120083464Abstract: The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament for the prevention or treatment of a neurological or psychiatric disease. The present invention also relates to a method of prevention or treatment of nerve cell death or damage, a method of neuroprotection, a method of regenerating nerve cells and a method of prevention or treatment of a neurological or psychiatric disease.Type: ApplicationFiled: June 7, 2010Publication date: April 5, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventor: Pablo Villoslada Diaz
-
Publication number: 20120082717Abstract: Disclosed herein is a complex, wherein micelles and/or liposomes dispersed in hyaluronic acids and/or hyaluronic acid derivatives, with a drug and/or functional material loaded in the micelles and/or the liposomes. The complex can release the drug and/or functional material in a controlled manner. Also, a multilayer using the complex, and a device coated with the multilayer are disclosed herein.Type: ApplicationFiled: June 4, 2010Publication date: April 5, 2012Applicants: SNU R&DB FOUNDATION, ILJIN MATERIALS CO., LTD.Inventors: Kook Heon Char, Sai Bom Park, Jin Hwa Seo, Sang Beom Kim, Chong Su Seo
-
Patent number: 8148348Abstract: Provided are a process for producing a S-adenosyl-L-methionine-containing composition which is very excellent in a stability by adding at least ascorbic acids or salts thereof to a composition liquid containing S-adenosyl-L-methionine and then drying the above composition liquid or separating and drying a crystallized deposit obtained from the above composition liquid, a S-adenosyl-L-methionine-containing composition obtained by the above production process and a molding obtained from the above composition.Type: GrantFiled: January 16, 2007Date of Patent: April 3, 2012Assignee: Mitsubishi Gas Chemical Company, Inc.Inventors: Kentarou Takano, Shinyo Gayama
-
Publication number: 20120077771Abstract: The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions.Type: ApplicationFiled: February 26, 2010Publication date: March 29, 2012Applicant: KING'S COLLEGE LONDONInventors: Hazem B. Fallouh, Jonathan C. Kentish, David J. Chambers
-
Publication number: 20120077770Abstract: Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxy-cholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary progressive MS (SPMS) using inhibitors of poly(ADP ribose) polymerase-1 (PARP-1).Type: ApplicationFiled: January 21, 2010Publication date: March 29, 2012Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Howard Weiner, Francisco J. Quintana, Mauricio Farez
-
Publication number: 20120071433Abstract: The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.Type: ApplicationFiled: May 12, 2010Publication date: March 22, 2012Inventors: Lucie Szucova, Viadimir Krystof, Marek Zatloukal, Karel Dolezal, Miroslav Strnad, Lukas Spichal
-
Publication number: 20120071432Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: March 18, 2011Publication date: March 22, 2012Applicant: The Regents of the University of ColoradoInventors: Daniel J. Abrams, Raymond Bunch, Tom Anchordoquy, Karen Elizabeth Stevens
-
Publication number: 20120071418Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.Type: ApplicationFiled: September 12, 2011Publication date: March 22, 2012Applicant: Epizyme, Inc.Inventors: Robert A. Copeland, Victoria M. Richon, Margaret D. Scott, Christopher J. Sneeringer, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock
-
Publication number: 20120070415Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.Type: ApplicationFiled: September 19, 2011Publication date: March 22, 2012Applicant: ALIOS BIOPHARMA, INC.Inventors: Leonid Beigelman, Jerome Deval, David Bernard Smith, Guangyi Wang, Vivek Kumar Rajwanshi
-
COMPOSITION CONTAINING A BEAN EXTRACT FOR IMPROVING BLOOD CIRCULATION AND INCREASING VASCULAR HEALTH
Publication number: 20120070520Abstract: The present invention relates to a composition containing a bean extract extracted by low-concentration, low-grade alcohol or fractions thereof. The composition exhibits excellent effects in improving blood circulation, improving obesity, and preventing diabetes, hyperlipidemia and the like, and exhibits the effects of alleviating or treating the symptoms of diabetes, hyperlipidemia, and the like. The present invention also relates to a method for improving blood circulation and vascular health.Type: ApplicationFiled: May 26, 2010Publication date: March 22, 2012Inventors: Hyun Jung Shin, Jin Kwan Kim, Chae Wook Kim, Kyung Mi Joo, Yeon Su Jeong, Kyung Min Lim, Dae-Bang Seo, Yung Hyup Joo, Sang Jun Lee, Young-Ho Park -
Publication number: 20120070369Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.Type: ApplicationFiled: December 10, 2009Publication date: March 22, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Othon Iliopoulos, Michael Zimmer
-
Publication number: 20120065155Abstract: The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A3R agonist.Type: ApplicationFiled: May 16, 2010Publication date: March 15, 2012Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Mordechai Farbstein
-
Publication number: 20120064127Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: November 11, 2011Publication date: March 15, 2012Applicant: N.V.NUTRICIAInventor: Robert J.J. Hageman
-
Patent number: 8133879Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds of structural formula shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging methods.Type: GrantFiled: March 29, 2010Date of Patent: March 13, 2012Assignee: Gilead Sciences, Inc.Inventors: Luiz Belardinelli, Mitchell Rosner
-
Patent number: 8133880Abstract: The invention relates to Purine Derivatives having the formula; The invention also relates to pharmaceutical compositions comprising an effective amount of the Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering an effective amount of the Purine Derivative to a subject in need thereof.Type: GrantFiled: November 12, 2010Date of Patent: March 13, 2012Assignee: Inotek Pharmaceuticals CorporationInventors: Prakash Jagtap, Andrew L. Salzman, Csaba Szabo
-
Patent number: 8129357Abstract: This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such as Huntington's disease, a trinucleotide repeat disease or abnormal blood glucose levels.Type: GrantFiled: December 6, 2007Date of Patent: March 6, 2012Assignee: Academia SinicaInventors: Yijuang Chern, Yun-Lian Lin, Nai-Kuei Huang, Jung-Hsing Lin, Jim-Min Fang, Chia-I Lin
-
Publication number: 20120053143Abstract: The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2?,3?,5?-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.Type: ApplicationFiled: March 10, 2009Publication date: March 1, 2012Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Haibo Zhu, Song Wu, Linghua Hao, Kai Qu, Ping Zhu, Xing Wang, Wei Li
-
Patent number: 8119614Abstract: The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound and use of these derivatives for preparation of pharmaceutical compositions, in biotechnological processes, in cosmetics and in agriculture.Type: GrantFiled: December 29, 2003Date of Patent: February 21, 2012Assignee: Ustav Experimentalni Botaniky Akademie Ved Ceske RepublikyInventors: Karel Dolezal, Igor Popa, Marek Zatloukal, René Lenobel, Dana Hradecká, Borivoj Vojtesek, Stjepan Uldrijan, Petr Mlejnek, Stefaan Werbrouck, Miroslav Strnad
-
Publication number: 20120040923Abstract: Stable compositions of defined non-racemic diastereomeric ratios of S-adenosyl-L-methionine, methods for their synthesis and methods for their uses are described. The compositions according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions.Type: ApplicationFiled: October 27, 2011Publication date: February 16, 2012Inventor: Rolland F. Hebert
-
Publication number: 20120034184Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: October 17, 2011Publication date: February 9, 2012Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Publication number: 20120027846Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Brian AGNEW, David GRAHAM, Upinder SINGH, Scott GRECIAN
-
Publication number: 20120027723Abstract: The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Inventor: Serge Picaud
-
Patent number: 8106029Abstract: Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.Type: GrantFiled: December 14, 2009Date of Patent: January 31, 2012Assignee: Gilead Sciences, Inc.Inventors: Toufigh Gordi, Ann Walls Olmsted, Hsiao Dee Lieu, Luiz Belardinelli
-
Publication number: 20120021989Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers.Type: ApplicationFiled: March 30, 2010Publication date: January 26, 2012Applicant: deCODE Genetics ehf.Inventors: Hilma Holm, Daniel Gudbjartsson
-
Publication number: 20120016467Abstract: Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.Type: ApplicationFiled: July 19, 2011Publication date: January 19, 2012Applicant: pSivida Inc.Inventors: Jianbing Chen, Paul Ashton, Thomas J. Smith
-
Patent number: 8097595Abstract: Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed.Type: GrantFiled: May 12, 2010Date of Patent: January 17, 2012Assignee: ALT Solutions, Inc.Inventor: Igor E. Bondarev
-
Patent number: 8093226Abstract: The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.Type: GrantFiled: January 15, 2009Date of Patent: January 10, 2012Assignee: Institute of Organic Chemistry and Biochemistry of the ASCR, V.V.I.Inventors: Michal Hocek, Petr Naus
-
Publication number: 20120004191Abstract: The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.Type: ApplicationFiled: July 1, 2011Publication date: January 5, 2012Applicant: ArQule, Inc.Inventors: Giovanni Abbadessa, Dennis S. France, Chang-Rung Chen, Thomas C.K. Chan
-
Patent number: 8088752Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.Type: GrantFiled: April 7, 2009Date of Patent: January 3, 2012Assignee: VDF FutureCeuticals, Inc.Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
-
Publication number: 20110312908Abstract: The present invention provides novel heteroaryl compounds that are linked to an aryl group via an amine linker. Such compounds are useful for the treatment of cancers.Type: ApplicationFiled: November 28, 2008Publication date: December 22, 2011Applicants: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang, Amy Wojciechowski
-
Patent number: 8080554Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.Type: GrantFiled: November 14, 2002Date of Patent: December 20, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Michail V. Sitkovsky, Akio Ohta
-
Patent number: 8076311Abstract: The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair.Type: GrantFiled: May 11, 2007Date of Patent: December 13, 2011Inventor: Patrick T. Prendergast
-
Publication number: 20110300081Abstract: The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologically acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases.Type: ApplicationFiled: January 11, 2010Publication date: December 8, 2011Applicant: GRAAL SRLInventor: Alessandro Seneci
-
Patent number: 8071566Abstract: The present invention provides methods of myocardial perfusion imaging and increasing coronary blood flow of a mammal that are accomplished by administering doses of a compound that is a selective partial A2A receptor agonist with a short duration of action, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, and determining areas of insufficient blood flow.Type: GrantFiled: May 4, 2009Date of Patent: December 6, 2011Assignee: Gilead Sciences, Inc.Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
-
Patent number: 8071565Abstract: Compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.Type: GrantFiled: July 11, 2007Date of Patent: December 6, 2011Assignee: Novartis AGInventors: Robin Alec Fairhurst, Roger John Taylor
-
Publication number: 20110293719Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: June 30, 2011Publication date: December 1, 2011Applicant: Ardea Biosciences, Inc.Inventors: Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
-
Patent number: 8063024Abstract: The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.Type: GrantFiled: January 26, 2006Date of Patent: November 22, 2011Assignee: University of ManitobaInventors: Wilfred Wayne Lautt, Zhi Ming
-
Patent number: 8058259Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: GrantFiled: December 18, 2008Date of Patent: November 15, 2011Assignee: University of Virginia Patent FoundationInventors: Robert Douglas Thompson, Anthony Beauglehole, Frank W. Schmidtmann, Jayson M. Rieger
-
Publication number: 20110269703Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 10, 2009Publication date: November 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Paul Anthony Reilly
-
Publication number: 20110269707Abstract: The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.Type: ApplicationFiled: August 5, 2010Publication date: November 3, 2011Inventors: Lieven Stuyver, Kyoichi Watanabe
-
Publication number: 20110262442Abstract: The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.Type: ApplicationFiled: November 8, 2010Publication date: October 27, 2011Applicant: Adenios, Inc.Inventors: Charles P. Hamilton, Nathan Dean Jorgensen
-
ANTIOXIDANT-CONTAINING FOOD COMPOSITION FOR USE IN ENHANCING ANTIVIRAL IMMUNITY IN COMPANION ANIMALS
Publication number: 20110256118Abstract: The invention encompasses methods for enhancing the ability of a companion animal to resist and/or overcome viral infections. The methods of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.Type: ApplicationFiled: December 16, 2009Publication date: October 20, 2011Applicant: Hill's Pet Nutrition, Inc.Inventors: Jeffrey A. Brockman, Nolan Zebulon Frantz, Steven C. Zicker -
Publication number: 20110257120Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: June 27, 2011Publication date: October 20, 2011Applicants: Idenix Pharmaceuticals, Inc., L'Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
-
Publication number: 20110251151Abstract: Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A1 receptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic™ and Compound A.Type: ApplicationFiled: March 18, 2011Publication date: October 13, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY
-
Patent number: 8034802Abstract: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.Type: GrantFiled: June 30, 2009Date of Patent: October 11, 2011Assignee: Anadys Pharmaceuticals, Inc.Inventor: Devron R. Averett
-
Publication number: 20110245195Abstract: Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).Type: ApplicationFiled: March 25, 2011Publication date: October 6, 2011Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Norman N. KIM, William K. MCVICAR, Thomas G. MCCAULEY, Prakash JAGTAP
-
Publication number: 20110244027Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.Type: ApplicationFiled: May 13, 2011Publication date: October 6, 2011Applicant: University of Georgia Research CenterInventors: Chung K. Chu, Jianing Wang